Machine learning may be a useful tool in predicting renal cell carcinoma tumor response to nivolumab monotherapy.
Advanced Renal Cell Carcinoma
Advertisement
Latest News
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on KEYNOTE-564, NEOAVAX, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CREST, ENLIGHTED, and more.
Dr. Brown breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG.
Dr. Brown discusses the latest TAR-200 data from the SunRISe-1 trial in BCG-unresponsive NMIBC, highlighting CR rates.
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Advertisement
Advertisement
Trending
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.
CN may improve OS for patients with metastatic nccRCC compared with systemic therapy alone, especially when combined with IO.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.